Search - tctmd.com

Displaying 241 - 260 of 515

Sort: Relevancy | Date

News Daily News

Grief and CVD: Simple Regimen May Lower Risk

L.A. McKeown

November 19, 2019

News Conference News AHA 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Yael L. Maxwell

November 19, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

News Daily News

Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD

Todd Neale

October 29, 2019

News Daily News

FDA: New Concerns Surface With Endologix Grafts for AAA

L.A. McKeown

October 28, 2019

News Daily News

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Shelley Wood

October 14, 2019

News Daily News

Sex-Specific Troponin Cutoffs Find Many More Women With Myocardial Injury

Todd Neale

October 14, 2019

News Conference News TCT 2019

Intravascular Lithotripsy Shows Good Safety at 30 Days: DISRUPT CAD II

Yael L. Maxwell

October 08, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

Yael L. Maxwell

September 01, 2019

News Features

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

Yael L. Maxwell

August 02, 2019

News Industry News

Miracor Medical Starts PiCSO-AMI-I Randomized Study in EU

July 25, 2019

News Industry News

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

July 15, 2019

News Daily News

Age Without Atherosclerosis: Tests May Help Elderly Skip Statins

Yael L. Maxwell

July 04, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

Shelley Wood

June 28, 2019

Advertisement

Grief and CVD: Simple Regimen May Lower Risk

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD

FDA: New Concerns Surface With Endologix Grafts for AAA

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Sex-Specific Troponin Cutoffs Find Many More Women With Myocardial Injury

Intravascular Lithotripsy Shows Good Safety at 30 Days: DISRUPT CAD II

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

Miracor Medical Starts PiCSO-AMI-I Randomized Study in EU

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

Age Without Atherosclerosis: Tests May Help Elderly Skip Statins

TCTMD’s Top 10 Most Popular Stories for June 2019

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content